Ali Akbar Kiaei

Dr. Ali Akbar Kiaei

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 September 2022 in Life
Verified
Journal Article
Open access
PDF file
AKAli Akbar Kiaei
Ali Akbar Kiaei
NSNader Salari
Nader Salari
MBMahnaz Boush
Mahnaz Boush
KMKamran Mansouri
Kamran Mansouri
AFAmin Hosseinian Far
Amin Hosseinian Far
Masoud MohammadiMasoud Mohammadi
Masoud Mohammadi
COVID-19 affects several human genes, each with its own p-value. The combination of drugs associated with these genes with small p-values may lead to an estimation of the combined p-value between COVID-19 and some drug combinations, thereby increasing the effectiveness of these combinations in defeating the disease. Based on human genes, we introduced a new machine learning method that offers an effective drug combination with low combined p-values between them and COVID-19. This study follows an improved approach to systematic reviews, called the Systematic Review and Artificial Intelligence Network Meta-Analysis (RAIN), registered within PROSPERO (CRD42021256797), in which, the PRISMA criterion is still considered. Drugs used in the treatment of COVID-19 were searched in the databases of ScienceDirect, Web of Science (WoS), ProQuest, Embase, Medline (PubMed), and Scopus. In addition, using artificial intelligence and the measurement of the p-value between human genes affected by COVID-19 and drugs that have been suggested by clinical experts, and reported within the identified research papers, suitable drug combinations are proposed for the treatment of COVID-19. During the systematic review process, 39 studies were selected. Our analysis shows that most of the reported drugs, such as azithromycin and hydroxyl-chloroquine on their own, do not have much of an effect on the recovery of COVID-19 patients. Based on the result of the new artificial intelligence, on the other hand, at a significance level of less than 0.05, the combination of the two drugs therapeutic corticosteroid + camostat with a significance level of 0.02, remdesivir + azithromycin with a significance level of 0.03, and interleukin 1 receptor antagonist protein + camostat with a significance level 0.02 are considered far more effective for the treatment of COVID-19 and are therefore recommended. Additionally, at a significance level of less than 0.01, the combination of interleukin 1 receptor antagonist protein + camostat + azithromycin + tocilizumab + oseltamivir with a significance level of 0.006, and the combination of interleukin 1 receptor antagonist protein + camostat + chloroquine + favipiravir + tocilizumab7 with corticosteroid + camostat + oseltamivir + remdesivir + tocilizumab at a significant level of 0.009 are effective in the treatment of patients with COVID-19 and are also recommended. The results of this study provide sets of effective drug combinations for the treatment of patients with COVID-19. In addition, the new artificial intelligence used in the RAIN method could provide a forward-looking approach to clinical trial studies, which could also be used effectively in the treatment of diseases such as cancer.

1 December 2025 in Journal of Big Data
Verified
Journal Article
Open access
PDF file
MZMohammad Zavvar
Mohammad Zavvar
MJMojtaba Jafari
Mojtaba Jafari
NPNarges Mohammadali Pour
Narges Mohammadali Pour
AKAli Akbar Kiaei
Ali Akbar Kiaei
MZMohammad Hossein Zavvar
Mohammad Hossein Zavvar
Nima Jafari NavimipourNima Jafari Navimipour
Nima Jafari Navimipour
Credit card fraud is still a big problem for banks and other financial organizations throughout the globe. It hurts consumer confidence and financial stabi

15 May 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
AKAli Akbar Kiaei
Ali Akbar Kiaei
MBMahnaz Boush
Mahnaz Boush
DSDanial Safaei
Danial Safaei
SASadegh Abadijou
Sadegh Abadijou
NBNima Baselizadeh
Nima Baselizadeh
MMMasoud Mohammadi
Masoud Mohammadi
Selecting the optimal activation function for training deep neural networks has always been challenging because it significantly impacts the neural network’s performance and training speed. At this point, researchers are more likely to employ RELU than other well-known activation functions. After RELU, researchers have proposed many activation functions to improve RELU. None of them was capable of surpassing RELU as their most significant rival. SWISH outperformed RELU in several challenging experiments like classification, object detection, and tracking. Replacing RELU units with SWISH, which improves performance in many tasks. This paper proposed a new activation function surpassing Google’s brain’s SWISH function, Which we named AIF. Experiments indicate that our proposed activation function outperforms SWISH in various tasks.

18 January 2025 in arXiv
Verified
Preprint
Open access
PDF file
RARaha Aghaei
Raha Aghaei
AKAli Akbar Kiaei
Ali Akbar Kiaei
MBMahnaz Boush
Mahnaz Boush
JVJavad Vahidi
Javad Vahidi
MZMohammad Zavvar
Mohammad Zavvar
MRMahan Rofoosheh
Mahan Rofoosheh
Large Language Models (LLMs) have revolutionized the process of customer engagement, campaign optimization, and content generation, in marketing management. In this paper, we explore the transformative potential of LLMs along with the current applications, future directions, and strategic recommendations for marketers. In particular, we focus on LLMs major business drivers such as personalization, real-time-interactive customer insights, and content automation, and how they enable customers and business outcomes. For instance, the ethical aspects of AI with respect to data privacy, transparency, and mitigation of bias are also covered, with the goal of promoting responsible use of the technology through best practices and the use of new technologies businesses can tap into the LLM potential, which help growth and stay one step ahead in the turmoil of digital marketing. This article is designed to give marketers the necessary guidance by using best industry practices to integrate these powerful LLMs into their marketing strategy and innovation without compromising on the ethos of their brand.

16 June 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
RBReza Bahadori
Reza Bahadori
AKAli Akbar Kiaei
Ali Akbar Kiaei
HMhourieh malekzadeh
hourieh malekzadeh
MBMahnaz Boush
Mahnaz Boush
SASadegh Abadijou
Sadegh Abadijou
AMAmir Hossein Mehdikhani
Amir Hossein Mehdikhani
Alzheimer's disease is a neurological illness that worsens gradually. It is known as the most frequent cause of dementia. Moreover, Alzheimer's disease is a general term for memory loss and other cognitive impairments severe enough to disrupt daily life. The disease often grows in middle-aged and elderly people with the gradual loss of cognitive ability. Since the diagnosis of the illness is time consuming, a novel machine learning approach is proposed in this research to diagnose Alzheimer's levels based on Magnetic Resonance Imaging (MRI). More specifically, to provide distinct information for classification we have implemented the proposed method on a native MRI scans dataset containing three MRI channels; namely T1, T2, and, T2 tirm, which are shown in red, blue and green, respectively. The five middle layers of these three types of MRI scans are combined to form five RGB layers. In addition, we use a Convolutional Neural Network to classify each composed layer, and the final disease type is predicted using majority voting. finally, the F1-Score has been used to assess method performance, indicated that 92% of predictions of the proposed model were accurate.

21 August 2023 in medRxiv
Verified
Preprint
Open access
PDF file
MBMahnaz Boush
Mahnaz Boush
AKAli Akbar Kiaei
Ali Akbar Kiaei
HMHossein Mahboubi
Hossein Mahboubi
Background Leukemia, a cancer impacting blood-forming tissues such as bone marrow and the lymphatic system, presents in various forms, affecting children and adults differently. The therapeutic approach is complex and depends on the specific leukemia type. Effective management is crucial as it disrupts normal blood cell production, increasing infection susceptibility. Treatments like chemotherapy can further weaken immunity. Thus, a patient’s healthcare plan should focus on comfort, reducing chemotherapy side effects, protecting veins, addressing complications, and offering educational and emotional support. Method This article reviews studies on the combined use of drugs for treating leukemia. Employing a mix of medicines might decrease the chances of tumor resistance. Starting multiple drugs concurrently allows for immediate application during disease onset, avoiding delays. Initial chemotherapy uses a drug combination to eliminate maximum leukemia cells and restore normal blood counts. Afterwards, intensification chemotherapy targets any residual, undetectable leukemia cells in the blood or bone marrow. To recommend a drug combination to treat/manage Leukemia, under first step of RAIN protocol, we have searched articles including related trend drugs using Natural Language Processing. In the second step, we have employed Graph Neural Network to pass information between these trending drugs and genes that act as potential targets for Leukemia. Result As a result, the Graph Neural network recommends combining Tretinoin, Asparaginase, and Cytarabine. The network meta-analysis confirmed the effectiveness of these drugs on associated genes. Conclusion The p-value between leukemia and the scenario that includes combinations of the mentioned drugs is almost zero, indicating an improvement in leukemia treatment. Reviews of clinical trials on these medications support this claim. Highlights Combined drugs that make p-value between Leukemia and target proteins/genes close to 1 Using Graph Neural network to recommend drug combination A Network meta-analysis to measure the comparative efficacy Considered drug interactions